Navigation Links
FDA to Address Industry Questions About Biosimilar Regulations at the Pharma's IQ Immunogenicity Event
Date:4/5/2011

LONDON, April 5, 2011 /PRNewswire/ -- This May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic Proteins CBER from FDA will meet with European industry experts at Pharma IQ's to discuss FDA directives on immunogenicity introduced in 2008.  

Over the last two years, the regulations have been subject interpretation. Although the regulations were released in 2008, there has been some confusion within the industry as the regulations are subject to interpretation. The confusion arises around the tests have to be developed in order to get approval to develop a drug with a suitable level of immunogenicity.

Joao will provide the attendees with the reviewed FDA regulations and an analysis of the FDA implementation policy. He will also discuss how new FDA guidelines will influence the product development and how companies could make the most out of the pending regulations.

During his presentation, he will also assess the changing regulatory landscape and the practicalities of regulatory approval establishing relationships between immunogenicity assay development studies.

FDA session, Regulatory Update: An FDA Guidance for Industry; Understand Policy and Ensure Assay Development Within the Guidelines, will be part of the 2nd Annual Immunogenicity: Prediction, Detection and Effective Assay Development event, taking part 30 May - 01 June 2011 in Munich.

Other key sessions include:

  • Implementing the correct immunogenicity assay for successful drug development with an A-Z of everything you need to know with Dan Sikkema, GlaxoSmithKline
  • Ensuring global regulatory compliance with key insights from Joao Pedras-Vasconcelos, FDA and Meenu Wadhwa, NIBSC
  • Discovering novel in vitro and in vivo assay techniques to improve immunogenicity prediction methods with Bruce Green, Pfizer
  • Effectively applying theory to practice with insights into comparative immunogenicity studies with Birgit Reipert, Baxter
  • Keeping up-to-date with industry advances with clinical updates on the role of compliment in nanomedicines and biologicals with Janos Szebeni, Nanomedicine Research and Education Center, Bay Zoltan Foundation
  • Case Study: Developing Safe and Efficacious Drugs: How immunogenicity is impacting clinical affects of drug development and safety by Andrew Yates, Senior Group Leader, Drug Research & Development UCB
  • Case Study: Developing Standardised Assays to Allow Direct Comparisons of the Immunogenicity of Innovator Products and Biosimilars

If you want to find out more, please visit http://www.immunogenicity-event.com/PR, email enquire@iqpc.co.uk or call 44 (0) 207 368 9400.

CONTACT:

PHARMA IQ
Joanna Checinska

email: joanna.checinska@iqpc.co.uk
phone: 44(0)2073689300


'/>"/>
SOURCE Pharma IQ
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
2. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
3. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
4. MannKind Addresses Pfizers Announcement Regarding Exubera
5. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
6. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
7. Four Alzheimers Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation
8. Isogen Launches Major New Facility to Address Global Biopharma Demand
9. WBAL Radio Segment With Dr. Leigh Vinocur Addresses Hope for the Rosacea Sufferer
10. Investigational Genetic Test May Help Address Common Problems in Prostate Cancer Diagnosis
11. FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a clinical ... through treatment, today announced that Carmine N. Stengone , president ... at the Needham & Company 16 th Annual Healthcare Conference ... PDT) at the Westin Grand Central Hotel in New ... ...
(Date:3/29/2017)... EAST HANOVER, N.J. , March 29, 2017 ... and Drug Administration (FDA) has accepted the company,s ... review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen ... refractory (r/r) pediatric and young adult patients with ... first BLA submission by Novartis for a CAR-T. ...
(Date:3/29/2017)... March 29, 2017 Today, CVS Health officials (NYSE: ... Reynolds , Department of Public Health Director Gerd Clabaugh ... Lukan in announcing the availability of the opioid overdose-reversal ... in Iowa.  CVS Health has established a standing order with ... Pharmacy to expand access to the medication in the state.   ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its ... Life" or "Wonder Spice", it has been used for thousands of years. , "The ... says Heshelow, author of " Turmeric: How to Use it For Your Wellness. Overcome ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 ... Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while ... HeartBoost, an over the counter heart healthy drink, can reduce Arterial Plaque, Lower ...
(Date:3/29/2017)... OK (PRWEB) , ... March 29, 2017 , ... ... now receive FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with ... straighten teeth efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, ...
(Date:3/29/2017)... ... March 29, 2017 , ... How big ... outpatient facilities, and who are the most active developers? , In the ... Healthcare Real Estate Insights (HREI) found that outpatient medical real estate development projects ...
(Date:3/29/2017)... ... 2017 , ... An inventor from Raynham, Mass., knows the ... conjunction with my braces always rubbed against the inside of my cheeks, causing ... problem." The O.B.S. was the result of his brainstorming. , This patent-pending invention ...
Breaking Medicine News(10 mins):